An open-label trial extension shows the novel anti-PCSK9 recombinant protein LIB003 markedly reduces lipid levels in heavily pretreated patients, although outcomes data are awaited, says expert. Medscape Medical News
Read More
Steep, Sustained Lipid Reductions Over Statins With LIB003

Recent Comments